|
Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry. |
| |
|
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Gilead Sciences (I); Lilly; MEDIS; MSD; Novartis; Pfizer; Roche/Genentech; Teva |
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; Progenetics; Roche |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; Roche |
| |
|
Employment - Rhenium/Oncotest |
Stock and Other Ownership Interests - Rhenium/Oncotest |
| |
|
Consulting or Advisory Role - Can-Fite BioPharma; Exact Sciences; Oncotest/Rhenium; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Genomic Health; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Gilead Sciences; Lilly; Novartis; Pfizer |
| |
|
Stock and Other Ownership Interests - Canfite; CTG Pharma; DocBoxMD; VYPE |
Research Funding - AstraZeneca/Merck (Inst); BioLineRx (Inst); Canfite (Inst); Halozyme (Inst); Moderna Therapeutics (Inst); Teva (Inst) |